IPP Bureau
Lonza to expand manufacturing drug substance for COVID-19 Vaccine Moderna
By IPP Bureau - June 03, 2021
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Haffkine Biopharma to produce 22.8 Cr doses of Covaxin
By IPP Bureau - June 03, 2021
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Lupin to foray into the digital healthcare space
By IPP Bureau - June 03, 2021
The company recently incorporated a new entity in the name of Lupin Digital Health Limited
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
By IPP Bureau - June 02, 2021
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
By IPP Bureau - June 02, 2021
Aurobindo has one of the most enduring generics ecosystems among peers
Lasa Supergenerics FY21 profit up 521%
By IPP Bureau - June 02, 2021
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Shilpa Medicare Q4FY21 consolidated PAT at Rs. 7.82 Cr
By IPP Bureau - June 01, 2021
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
Marksans Pharma Q4 FY21 profit up 86%
By IPP Bureau - June 01, 2021
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Jubilant to invest US $92 mn to expand sterile injectable capacity
By IPP Bureau - June 01, 2021
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Govt. to give 12 Cr COVID vaccine doses in June 2021
By IPP Bureau - May 31, 2021
7.94 crore doses were made available to the states in May 2021
Margins impacted by high expenses for Pfizer: ICICI Securities
By IPP Bureau - May 31, 2021
Adjusted PAT declined 18.8% YoY
Sun Pharmaceutical’s internals remain strong: ICICI Securities
By IPP Bureau - May 31, 2021
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
By IPP Bureau - May 31, 2021
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr
By IPP Bureau - May 31, 2021
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
IPCA Q4FY21 consolidated net profit slides QoQ to Rs. 161.34 Cr
By IPP Bureau - May 29, 2021
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
